Neurofilament light chain predicts disease activity in relapsing-remitting MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 1, 2017
- Accepted in final form September 29, 2017
- First Published November 29, 2017.
Author Disclosures
- Kristin N. Varhaug, MD,
- Christian Barro, MD,
- Kjetil Bjørnevik, MD,
- Kjell-Morten Myhr, MD, PhD,
- Øivind Torkildsen, MD, PhD,
- Stig Wergeland, MD, PhD,
- Laurence A. Bindoff, MD, PhD,
- Jens Kuhle, MD, PhD and
- Christian Vedeler, MD, PhD
- Kristin N. Varhaug, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Barro, MD,
NONE
NONE
Travel support by Teva and Novartis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kjetil Bjørnevik, MD,
(1) Scientific advisory board for Biogen
NONE
NONE
(1) Frontiers in Neurology, editorial board member, 2017-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kjell-Morten Myhr, MD, PhD,
Scientific advisory board (non-profit entity)for Novartis Norway, Biogen, Genzyme and Roche.
NONE
Funding for travel (non-profit entity)from, Sanofi Aventis, Novartis, and Biogen. Speaker honoraria (non-profit entity) from, Genzyme, Sanofi-Aventis, Novartis, Biogen, Roche and Almirall.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research support from from, Sanofi Aventis, Novartis, Biogen, Pronova and Norwegian MS Society.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Øivind Torkildsen, MD, PhD,
1) Biogen Idec 2) Sanofi-aventis 3) Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stig Wergeland, MD, PhD,
NONE
NONE
1) Biogen, honoraria as speaker. 2) Novartis, honoraria as speaker. 3) Norwegian MS Society, honoraria as speaker. 4) Sanofi-Aventis, honoraria as speaker.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laurence A. Bindoff, MD, PhD,
1. Commercial: Medical Adjudication Committee for Stealth Biotherapeutics
NONE
NONE
1. Editorial Board Neuromuscular Diseases. ca. 2000 -
NONE
NONE
1. Stealth Biotherapuetics. Medical Adjudication committtee
NONE
NONE
NONE
NONE
NONE
NFR. 229652. 2015-18
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jens Kuhle, MD, PhD and
NONE
NONE
JK?s institution (University Hospital Basel) received in the last 3 years and used exclusively for research support: Speaker honoraria: (1) Swiss MS Society (2) Biogen (3) Novartis (4) Roche (5) Genzyme Travel expenses: (1) Merck Serono (2) Novartis (3) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Bayer AG (2) Biogen (2) Genzyme (3) Merck (4) Novartis (5) Roche Pharma (Schweiz) AG
(1) Swiss National Research Foundation
NONE
(1) ECTRIMS Research Fellowship Programme (2) University of Basel (3) Swiss MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Vedeler, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (K.N.V., K.B., K.-M.M., Ø.T., S.W., L.A.B., C.V.), Haukeland University Hospital; Department of Clinical Medicine (K.N.V., K.-M.M., Ø.T., S.W., L.A.B., C.V.), University of Bergen, Norway; Neurologic Clinic and Policlinic (C.B., J.K.), Departments of Medicine, Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Global Public Health and Primary Care (K.B.), University of Bergen, Norway; and Norwegian MS-Registry & Biobank (K.-M.M.).
- Correspondence to Dr. Varhaug: Kristin.nielsen.varhaug{at}helse-bergen.no
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MSSinah Engel, Michaela Friedrich, Muthuraman Muthuraman et al.Neurology: Neuroimmunology & Neuroinflammation, July 19, 2019 -
Article
High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MSSimon Thebault, Daniel R. Tessier, Hyunwoo Lee et al.Neurology: Neuroimmunology & Neuroinflammation, August 09, 2019 -
Article
Serum NFL discriminates Parkinson disease from atypical parkinsonismsTainá M. Marques, Anouke van Rumund, Patrick Oeckl et al.Neurology, February 27, 2019 -
Article
Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosisEmily Feneberg, Patrick Oeckl, Petra Steinacker et al.Neurology, December 06, 2017